Ethics test: Who gets experimental Ebola drug?

Global Business

Shares of Canada’s Tekmira Pharmceuticals soared for a second straight day. Last week, the U.S. Food and Drug Administration fast-tracked its experimental drug, TKM Ebola. The company will be allowed to resume human clinical trials on its experimental treatment.

In trials TKM Ebola showed promise, providing 100 percent protection of non-human primates infected with a lethal dosage of the Zaire Ebola Virus.

For the day, Tekmira shares jumped 15 percent.

Medical ethicists are now weighing who should get Ebola drugs, and when. CCTV America spoke to Doctor Ford Vox, a physician based out of Atlanta.

As the Ebola outbreak continues to claim lives in West Africa, the region’s governments count the economic cost of the virus. Liberia had just begun to see economic growth after a decade of peace, but the outbreak will set the country back.
Katerina Vittozzi has more.